Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: A meta-analysis

Reproductive BioMedicine Online

Volumn 16, Issue 1, 2008, Pages 81-88

  Al Inany, Hesham G ^a,b,c   Abou Setta, Ahmed M ^b   Aboulghar, Mohamed A ^a,b   Mansour, Ragaa T ^a   Serour, Gamal I ^a  

^a Egyptian International Fertility IVF ET Center   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c NONE   (Egypt)

Author keywords

FSH; HMG; Meta analysis; Ovulation stimulation; Recombinant

Indexed keywords

HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; META ANALYSIS; MULTIPLE PREGNANCY; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; RISK ASSESSMENT; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 38849201876     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60559-7     Document Type: Article

References (40)

1. Al-Inany H, Aboulghar MA, Mansour RT, Serour GI 2005 Ovulation induction in the new millennium: recombinant follicle-stimulating hormone versus human menopausal gonadotropin. Gynecological Endocrinology 20, 161-169.
2. Al-Inany H, Aboulghar M, Mansour R, Serour G 2003 Meta-analysis of recombinant versus urinary-derived FSH: an update. Human Reproduction 18, 305-313.
3. Andersen AN, Devroey P, Arce JC 2006 Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Human Reproduction 21, 3217-3227.
4. Andersen AN, Devroey P, Arce JC, for the MERIT (Menotrophin vs Recombinant FSH in vitro Fertilisation Trial) Group 2005 A randomized trial (MERIT) comparing highly purified menotropin and recombinant FSH in IVF. Human Reproduction 20, (Suppl. 1), i19.
5. Balasch J, Penarrubia J, Fabregues F et al. 2003 Ovarian responses to recombinant FSH or hMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction. Reproductive BioMedicine Online 7, 35-42.
6. Balasch J, Fabregues F, Creus M et al. 1996 Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization. Human Reproduction 11, 2400-2404.
7. Bosch E, Pau E, Albert C et al. 2005a HMG vs. r-FSH + rLH: analysis of hormonal serum and follicular profiles, and cycle outcome in oocyte donation. Fertility and Sterility 84 (Suppl. 1), S257-S258.
8. Bosch E, Vidal C, Crespo J et al. 2005b Highly purified HMG versus rec-FSH in GnRH antagonist cycles. Human Reproduction 20 (Suppl. 1), i118.
9. Collins J 2003 A turbulent arena. Fertility and Sterility 80, 1117-1120.
10. Commenges-Ducos M, Piault S, Papaxanthos A et al. 2002 Recombinant follicle-stimulating hormone versus human menopausal gonadotropin in the late follicular phase during ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility 78, 1049-1054.
11. Cook RJ, Sackett DL 1995 The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal 310, 452-454.
12. Cooke AS, Webster BW, Terranova PF, Keel BA 1988 Variation in the biologic and biochemical characteristics of human menopausal gonadotropin. Fertility and Sterility 49, 704-712.
13. Drakakis P, Loutradis D, Kallianidis K et al. 2002 The clinical efficacy of recombinant FSH (r-FSH) as compared to highly purified urinary gonadotrophin (hMG-FD) and the use of a low starting dose of r-FSH in IVF or ICSI. Italian Journal of Gynæcology and Obstetrics 14, 64-68.
14. Duijkers IJ, Willemsen WN, Hollanders HM et al. 1997 Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. II. Comparison of hMG and recombinant FSH. International Journal of Fertility and Women's Medicine 42, 431-435.
15. European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone 2002 Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertility and Sterility 78, 520-528.
16. Giudice E, Crisci C, Altarocca V, O'Brien M 2001 Characterisation of a partially purified human menopausal gonadotropin preparation. Journal of Clinical Research 4, 27-33.
17. Gordon UD, Harrison RF, Fawzy M et al. 2001 A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertility and Sterility 75, 324-331.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG 2003 Measuring inconsistency in meta-analyses. British Medical Journal 327, 557-560.
19. Hompes PG, Broekmans FJ, Hoozemans DA, Schats R, for the FIRM Group 2007 Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertility and Sterility [Epub ahead of print Aug 4].
20. Jansen CA, van Os HC, Out HJ, Coelingh Bennink HJ 1998 A prospective randomized, clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in vitro fertilization patients. Human Reproduction 13, 2995-2999.
21. Kilani Z, Dakkak A, Ghunaim S et al. 2003 A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Human Reproduction 18, 1194-1199.
22. Kornilov NV, Shlykova SA, Loginova JA 1999 Comparison of four different gonadotropins for ovarian stimulation in IVF treatment [abstract]. 11th World Congress on In Wtro Fertilization and Human Reproductive Genetics, 1999 May, Sydney, Australia. Monduzzi, Bologna (Italy), 1999, pp. 379-383.
23. Loutradis D, Kallianidis K Drakakis P 1998 A prospective randomised study to evaluate the clinical efficacy of recFSH as compared to hMG-FD in IVF-ET. Fertility and Sterility 70, S432.
24. Mahmoud K, Zhioua F, Kefi-Attaoui L 2001 Controlled ovarian stimulation (COS) in assisted reproductive technologies: r-FSH alone or r-FSH and hMG combined? [abstract]. Human Reproduction (abstract book) 16, 92. Abstract O-224.
25. Meo F, Ranieri DM, Khadum I, Serhal P 2002 Ovarian response and in vitro fertilization outcome in patients with reduced ovarian reserve who were stimulated with recombinant follicle stimulating hormone or human menopausal gonadotropin. Fertility and Sterility 77, 630-632.
26. Ng EH, Lau EY, Yeung WS, Ho PC 2001 hMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial. Human Reproduction 16, 319-325.
27. Out HJ, Mannaerts B, Driessen S, Coelingh Bennink HJ 1996 Recombinant follicle stimulating hormone (r-FSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies. Human Reproduction Update 2, 162-171.
28. Rashidi BH, Sarvi F, Tehrani ES et al. 2005 The effect of HMG and recombinant human FSH on oocyte quality: a randomized single-blind clinical trial. European Journal of Obstetrics & Gynecology and Reproductive Biology 120, 190-194.
29. Smitz J, Andersen AN, Devroey P et al. 2007 Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Human Reproduction 22, 676-687.
30. Smitz J, Andersen AN, Devroey P et al. 2005 Endocrine profile after stimulation with highly purified menotropin and recombinant FSH in IVF cycles. Human Reproduction 20 (Suppl. 1), i76.
31. Stokman PG, de Leeuw R, van den Wijngaard HA et al. 1993 Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertility and Sterility 60, 175-178.
32. Strehler E, Abt M, El-Danasouri I et al. 2001 Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome. Fertility and Sterility 75, 332-336.
33. Sykes D, Out HJ, Palmer SJ, van Loon J 2001 The cost effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments. Human Reproduction 16, 2557-2562.
34. van de Weijer BH, Mulders JW, Bos ES et al. 2003 Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reproductive BioMedicine Online 7, 547-557.
35. Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F 2003 Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews (1), CD003973.
36. Westergaard LG, Erb K, Laursen SB et al. 2001 Human menopausal gonadotropin versus recombinant follicle- stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertility and Sterility 76, 543-549.
37. Yusuf S, Peto R, Lewis J et al. 1985 Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases 27, 335-371.
38. Ziebe S, Lundin K, Janssens R et al. 2007 Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Human Reproduction 22, 2404-2413.
39. Ziebe S, Lundin K, Janssens R et al. 2005 Comparison of embryo quality with highly purified menotropin and recombinant FSH in IVF cycles. Human Reproduction 20 (Suppl. 1), i76.
40. Zygmunt M, Herr F, Keller-Schoenwetter S et al. 2002 Characterization of human chorionic gonadotropin as a novel angiogenic factor. Journal of Clinical Endocrinology and Metabolism 87, 5290-5296.